Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma

Hematology Journal

Volumn 5, Issue 4, 2004, Pages 312-317

  Offiddani, Massimo ^a   Corvatta, Laura ^a   Marconi, Monica ^a   Olivieri, Attilio ^a   Catarini, Massimo ^b   Mele, Anna ^c   Brunori, Marino ^d   Candela, Marco ^a   Malerba, Lara ^a   Capelli, Debora ^a   Montanari, Mauro ^a   Leoni, Pietro ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Macerata Hospital   (Italy)

^c SAN SALVATORE HOSPITAL   (Italy)

^d Fano Hospital   (Italy)

Author keywords

Melphalan; Multiple myeloma; Response; Thalidomide; Toxicity

Indexed keywords

BETA 2 MICROGLOBULIN; HEMOGLOBIN; IMMUNOGLOBULIN G; MELPHALAN; PARAPROTEIN; THALIDOMIDE; THYROID HORMONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRADYCARDIA; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; INFECTION; LEUKOPENIA; MALE; MOOD DISORDER; MULTICENTER STUDY; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; SOMNOLENCE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 4544321241     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200401     Document Type: Article

References (34)

1. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity in thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
2. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 89-96.
3. Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M et al. Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br J Haematol 2000; 108: 391-393.
4. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
5. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003; 78: 34-39.
6. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
7. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
8. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-3073.
9. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82: 3712-3720.
10. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-[kappa]. Blood 1996; 87: 1104-1112.
11. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950-1961.
12. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885-1892.
13. Davies FE, Raje N, Hideshima T, Lenzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivates augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
14. Damiano JS, Cress AE, Hazleurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell line. Blood 1999; 93: 1658-1667.
15. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991-995.
16. Weber DM, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide with dexamethasone for resistant multiple myeloma (abstract). Blood 2001; 98 (Suppl 1): 167a.
17. Palumbo A, Bertola A, Cavallo F, Falco P, Bringhen S, Giaccone L et al. Low-dose thalidomide and dexamethasone improve survival in advanced multiple myeloma (abstract). Blood 2002; 100 (Suppl 1): 211a.
18. Munshi N, Desikan R, Zangari M, Badros A, Chodimella U, Toor A et al. Chemoangiotherapy with DT-PACE for previously treated multiple myeloma (MM) (abstract). Blood 1999; 94 (Suppl 1): 123a.
19. Mohler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001; 98: 3846-3848.
20. Samson D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 10: 1115-1123.
21. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
22. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Alexanian R, Dimopoulos MA. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484-489.
24. Oakervee H, Baugh H, Boots M, Olujohungbe A, Smith S, Williams C et al. A study of the safety and efficacy of oral melphalan, prednisolone and thalidomide (MPT) in the treatment of multiple myeloma: a UK Myeloma Forum Pilot Study (abstract). Br J Haematol 2002; 117 (Suppl. 1): 66.
25. Srkalovic G, Elson P, Trebisky B, Karam MA, Hussein MA. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol 2002; 19: 219-226.
26. Durie BGM, Stepan DE. Low dose thalidomide alone and in combination: long term follow-up (abstract). Blood 2001; 98 (Suppl. 1): 163a.
27. Tosi P, Cellini E, Cangini D, Tura S, Baccarani M, Cavo M. Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractory multiple myeloma (abstract). Blood 2001; 98 (Suppl. 1): 163a.
28. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768-771.
29. Dimopoulos MA, Panayiotidis P, Grigoraki V, Poziopoulos C, Xilouri I, Kiamouris C et al. Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma (abstract). Blood 2001; 98 (Suppl. 1): 164a.
30. Hussein MA, Elson P, Tsoe EA, Karam M, Srkaloci G. Doxil (D), vincristine (V), decadron (d) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM) (abstract). Blood 2002; 100 (Suppl. 1): 403a.
31. Kropff MH, Lang N, Bisping G, Domin N, Schneider P, Suedhoff T et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma (abstract). Blood 2002; 100 (Suppl. 1): 402a.
32. Oakervee H, McBride NC, Hemmaway CJ, Brownell A, Cervi P, Crawley C et al. Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting (abstract). Blood 2002; 100 (Suppl. 1): 402a.
33. Cavenagh J. Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120: 18-26.
34. Barlogie B, Tricot G, Anaissie E, Fassas A, Lee CK, Thertulien R et al. Long-term follow-up (median of 4 yr) of 169 patients receiving thalidomide (THAL) for advanced and refractory multiple myeloma (MM) superior survival in the absence of cytogenetic abnormalities (CA) and low β-2 microglobulin (B2M) (abstract). Blood 2002; 10 (Suppl. 1): 210A.